These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 12589451

  • 1. [The molecular mechanisms of neovascular age-related macular degeneration].
    Miller DW, Joussen AM, Holz FG.
    Ophthalmologe; 2003 Feb; 100(2):92-6. PubMed ID: 12589451
    [Abstract] [Full Text] [Related]

  • 2. [Pathogenesis of choroidal neovascularization. Old concepts, new questions].
    Fauser S, Engelmann K, Krohne TU, Lappas A, Kirchhof B, Joussen AM.
    Ophthalmologe; 2003 Apr; 100(4):300-5. PubMed ID: 12682762
    [Abstract] [Full Text] [Related]

  • 3. [Pharmacological therapy for age-related macular degeneration. Current developments and perspectives].
    Holz FG, Miller DW.
    Ophthalmologe; 2003 Feb; 100(2):97-103. PubMed ID: 12589452
    [Abstract] [Full Text] [Related]

  • 4. Wet age-related macular degeneration.
    Kulkarni AD, Kuppermann BD.
    Adv Drug Deliv Rev; 2005 Dec 13; 57(14):1994-2009. PubMed ID: 16309781
    [Abstract] [Full Text] [Related]

  • 5. Age-related macular degeneration.
    Brucker AJ.
    Retina; 2009 Jun 13; 29(6 Suppl):S2-4. PubMed ID: 19553791
    [Abstract] [Full Text] [Related]

  • 6. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec 13; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 7. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration.
    Grisanti S, Tatar O.
    Prog Retin Eye Res; 2008 Jul 13; 27(4):372-90. PubMed ID: 18621565
    [Abstract] [Full Text] [Related]

  • 8. [Neovascularization in ocular tissues: mechanisms and role of proangiogenic and antiangiogenic factors].
    Nowak JZ, Wiktorowska-Owczarek A.
    Klin Oczna; 2004 Jul 13; 106(1-2):90-7. PubMed ID: 15218775
    [Abstract] [Full Text] [Related]

  • 9. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration.
    Campochiaro PA, Soloway P, Ryan SJ, Miller JW.
    Mol Vis; 1999 Nov 03; 5():34. PubMed ID: 10562658
    [Abstract] [Full Text] [Related]

  • 10. [Progress on study of treatment of age-related macular degeneration by pigment epithelial-derived factor].
    Hou HY, Wang YS.
    Zhonghua Yan Ke Za Zhi; 2010 Feb 03; 46(2):181-5. PubMed ID: 20388353
    [Abstract] [Full Text] [Related]

  • 11. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
    Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS.
    Am J Ophthalmol; 2006 Mar 03; 141(3):456-62. PubMed ID: 16490490
    [Abstract] [Full Text] [Related]

  • 12. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N, Damico L, Shams N, Lowman H, Kim R.
    Retina; 2006 Oct 03; 26(8):859-70. PubMed ID: 17031284
    [Abstract] [Full Text] [Related]

  • 13. [Angiogenic inducers and inhibitors].
    Shukunami C, Hiraki Y.
    Tanpakushitsu Kakusan Koso; 2000 Sep 03; 45(13 Suppl):2131-8. PubMed ID: 11021214
    [No Abstract] [Full Text] [Related]

  • 14. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration.
    Mruthyunjaya P, Stinnett SS, Toth CA.
    Ophthalmology; 2004 Sep 03; 111(9):1715-24. PubMed ID: 15350328
    [Abstract] [Full Text] [Related]

  • 15. Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial.
    Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research GroupCAPT Coordinating Center, University of Pennsylvania, Philadelphia, PA 19104-3309, USA..
    Ophthalmology; 2008 Sep 03; 115(9):1474-9, 1479.e1-6. PubMed ID: 18502512
    [Abstract] [Full Text] [Related]

  • 16. Guidance for the treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcòstegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO, European Society for Retina Specialists' Guidelines Committee (EURETINA).
    Acta Ophthalmol Scand; 2007 Aug 03; 85(5):486-94. PubMed ID: 17655610
    [Abstract] [Full Text] [Related]

  • 17. [New therapeutic approaches to age dependent macular degeneration].
    Holz FG.
    Ophthalmologe; 2003 Feb 03; 100(2):90-1. PubMed ID: 12653082
    [No Abstract] [Full Text] [Related]

  • 18. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L, Ruiz-Moreno JM, Gómez-Ulla F, Fernández M, Montero J.
    Retina; 2009 Feb 03; 29(10):1444-9. PubMed ID: 19730163
    [Abstract] [Full Text] [Related]

  • 19. [Age-related macular degeneration; therapeutic options].
    La Heij EC, Liem AT, Hendrikse F.
    Ned Tijdschr Geneeskd; 2001 Jul 21; 145(29):1390-7. PubMed ID: 11494688
    [Abstract] [Full Text] [Related]

  • 20. Prophylactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients.
    Friberg TR, Musch DC, Lim JI, Morse L, Freeman W, Sinclair S, PTAMD Study Group.
    Ophthalmology; 2006 Apr 21; 113(4):622.e1. PubMed ID: 16581422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.